SMS Pharma Q1FY27 Revenue Up 6% to ₹207 Cr, PAT Grows 8% to ₹20.2 Cr
SMS Pharma reported Q1FY27 revenue of ₹207 crore, up 6% YoY, with PAT at ₹20.2 crore, up 8% YoY. EBITDA margin remained at 20%. The company completed 4 DMF/CEP filings and is on track for its FY27 target of 10 filings. A ₹50 crore loan will be infused into subsidiary SMS Peptides Private Limited.
The results show steady growth and strategic investments, which are positive for the company's future, but do not represent a significant, transformative event.
The company reported growth in revenue and PAT, maintained healthy margins, and is progressing with its R&D and Capex plans, indicating positive performance and future outlook.
SMS Pharmaceuticals Limited (SMS Pharma) announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a 6% year-on-year (YoY) increase in revenue from operations, reaching ₹207.0 crore, driven by broad-based growth across its high-value Active Pharmaceutical Ingredients (API) portfolio. The Anti Retro Viral (ARV) portfolio saw strong growth, alongside continued healthy demand for Ibuprofen from regulated markets.
Gross profit increased by 12% YoY to ₹74.9 crore, with the gross margin expanding 217 basis points to 36%, attributed to benefits from backward integration and an improved product mix. EBITDA stood at ₹40.95 crore, a 4% YoY increase, maintaining a healthy EBITDA margin of 20%. Profit After Tax (PAT) grew by 8% YoY to ₹20.20 crore, with the PAT margin remaining stable at 10%. The company also reported ₹0.71 crore as share of profit from its associate, VKT Pharma Private Limited, resulting in a net profit after tax and associate profit of ₹20.91 crore.
Mr. P. Vamsi Krishna, Executive Director, commented that the company started FY27 on a healthy note, with consistent EBITDA margins around 20%. He noted that while structural margins are improving, EBITDA margins were impacted by annual employee increments and elevated freight costs due to geopolitical situations in West Asia. These headwinds are expected to ease, supporting future margin expansion.
On the R&D front, SMS Pharma completed 4 Drug Master File (DMF) and Certificate of Suitability (CEP) filings during the quarter, positioning them to meet their FY27 target of 10 such filings. The R&D team has developed a pipeline of 6 to 8 niche and high-value molecules expected to enter commercial production by the end of the financial year. The company is also allocating an additional ₹50 crore as a loan to its subsidiary, SMS Peptides Private Limited, to build its peptide CDMO platform, following an ₹8 crore investment in FY26.
The ₹280 crore Capex program is progressing as planned, with ₹120 crore completed and the remaining ₹160 crore expected to be finished by FY27. This investment will support the commercialization of new niche and high-value molecules. Looking ahead, SMS Pharma is confident in delivering its FY27 growth guidance with sustained EBITDA margins of 20%, supported by capacity expansion, new molecule commercialization, and growth in its ARV and anti-inflammatory product portfolios.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.